Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?

Over the past two decades, the treatment landscape for multiple myeloma (MM) has progressed significantly, with the introduction of several new drug classes that have greatly improved patient outcomes. At present, it is well known how the bone marrow (BM) microenvironment (ME) exerts an immunosuppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertuglia, Giuseppe, Cani, Lorenzo, Larocca, Alessandra, Gay, Francesca, D’Agostino, Mattia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781462/
https://www.ncbi.nlm.nih.gov/pubmed/36555520
http://dx.doi.org/10.3390/ijms232415879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781462/
https://www.ncbi.nlm.nih.gov/pubmed/36555520
http://dx.doi.org/10.3390/ijms232415879

Ejemplares similares